Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 6 | 2022 | 154 | 1.780 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2012 | 232 | 1.030 |
Why?
|
| Carcinogenesis | 2 | 2022 | 20 | 0.920 |
Why?
|
| Adenoma | 2 | 2022 | 58 | 0.880 |
Why?
|
| Lung Neoplasms | 6 | 2012 | 536 | 0.870 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 78 | 0.830 |
Why?
|
| DNA Damage | 1 | 2021 | 27 | 0.740 |
Why?
|
| Glioblastoma | 1 | 2021 | 12 | 0.730 |
Why?
|
| MicroRNAs | 1 | 2022 | 42 | 0.730 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 53 | 0.730 |
Why?
|
| Carcinoma | 1 | 2022 | 65 | 0.720 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 83 | 0.690 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2021 | 13 | 0.690 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2021 | 29 | 0.660 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 134 | 0.500 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 101 | 0.470 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 109 | 0.430 |
Why?
|
| Genes, p16 | 1 | 2012 | 4 | 0.400 |
Why?
|
| Quinazolines | 3 | 2012 | 16 | 0.380 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 14 | 0.380 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 162 | 0.360 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2020 | 34 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2007 | 42 | 0.330 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 8 | 0.330 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 11 | 0.330 |
Why?
|
| Aged | 15 | 2021 | 8382 | 0.330 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 15 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 33 | 0.330 |
Why?
|
| Female | 17 | 2021 | 14048 | 0.320 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 0.310 |
Why?
|
| Humans | 22 | 2022 | 24703 | 0.310 |
Why?
|
| Endometrial Neoplasms | 2 | 2021 | 25 | 0.310 |
Why?
|
| Middle Aged | 12 | 2021 | 8294 | 0.300 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 76 | 0.290 |
Why?
|
| Adult | 9 | 2021 | 7255 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 3 | 0.270 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 182 | 0.240 |
Why?
|
| Age Factors | 2 | 2021 | 728 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 374 | 0.240 |
Why?
|
| Male | 12 | 2021 | 13669 | 0.230 |
Why?
|
| Genetic Testing | 2 | 2016 | 54 | 0.230 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 55 | 0.210 |
Why?
|
| DNA Repair Enzymes | 2 | 2016 | 8 | 0.210 |
Why?
|
| GTP Phosphohydrolases | 2 | 2020 | 6 | 0.210 |
Why?
|
| Genes, BRCA1 | 2 | 2020 | 12 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 62 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 21 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2020 | 159 | 0.190 |
Why?
|
| Genes, p53 | 2 | 2020 | 19 | 0.190 |
Why?
|
| Prognosis | 3 | 2018 | 674 | 0.190 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 7 | 0.180 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 9 | 0.170 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 5 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 3 | 0.170 |
Why?
|
| Intestinal Mucosa | 1 | 2022 | 150 | 0.170 |
Why?
|
| Survival Rate | 2 | 2012 | 285 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 332 | 0.170 |
Why?
|
| Phthalazines | 1 | 2020 | 6 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 5 | 0.160 |
Why?
|
| Piperazines | 1 | 2020 | 75 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 183 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2021 | 254 | 0.150 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 8 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 157 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2018 | 43 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 44 | 0.150 |
Why?
|
| Hematopoiesis | 1 | 2018 | 11 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 3 | 0.150 |
Why?
|
| Chimerism | 1 | 2018 | 5 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 5 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 5 | 0.150 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 6 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2018 | 33 | 0.140 |
Why?
|
| X-linked Nuclear Protein | 1 | 2017 | 2 | 0.140 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2017 | 2 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 4 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 85 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 39 | 0.130 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 3 | 0.130 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 6 | 0.130 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 4 | 0.130 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 9 | 0.130 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 10 | 0.130 |
Why?
|
| Mutation | 5 | 2018 | 307 | 0.130 |
Why?
|
| ErbB Receptors | 4 | 2012 | 49 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 84 | 0.120 |
Why?
|
| Young Adult | 1 | 2021 | 1847 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4509 | 0.120 |
Why?
|
| CpG Islands | 2 | 2017 | 52 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 138 | 0.110 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2018 | 555 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 24 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2013 | 14 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 87 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2012 | 3208 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 24 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1539 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 348 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 77 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 18 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2012 | 75 | 0.090 |
Why?
|
| Illinois | 1 | 2012 | 221 | 0.090 |
Why?
|
| Meiosis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Disease Progression | 2 | 2018 | 632 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2010 | 14 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 11 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2010 | 20 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2010 | 36 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 105 | 0.080 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1671 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 27 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 29 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 47 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 49 | 0.080 |
Why?
|
| Lung | 1 | 2010 | 153 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 37 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 29 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 21 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 113 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 198 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2007 | 231 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 108 | 0.060 |
Why?
|
| Patient Selection | 1 | 2007 | 177 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 303 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3156 | 0.060 |
Why?
|
| Logistic Models | 1 | 2007 | 365 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 370 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 358 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2021 | 18 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 79 | 0.040 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2020 | 10 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2021 | 72 | 0.040 |
Why?
|
| Standard of Care | 1 | 2020 | 8 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 412 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 315 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 13 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Galectins | 1 | 2018 | 5 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 21 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2018 | 22 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2018 | 18 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 131 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 437 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 196 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 50 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1327 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 532 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 41 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2012 | 18 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 280 | 0.020 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2010 | 1 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 55 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 110 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 413 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 4 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 6 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 11 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 43 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 37 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2008 | 30 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 145 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 13 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 193 | 0.020 |
Why?
|